Journal issues > Issue 1, February 2024 > Highlights in acute myeloid leukaemia

Highlights in acute myeloid leukaemia

SUMMARY

The 2023 annual meeting of the American Society of Hematology (ASH) again featured some interesting studies related to acute myeloid leukaemia (AML). In newly diagnosed patients, the FLT3 inhibitor quizartinib and the combination of ivosidenib and a hypomethylating agent (HMA) yielded promising results in patients harbouring a FLT3-internal tandem duplication (ITD) or IDH1 mutation, respectively. Additionally, the nuclear export inhibitor selinexor, combined with azacitidine and venetoclax (SAV), resulted in encouraging responses in unfit AML patients. In the relapsed/refractory (R/R) setting, the menin inhibitor revumenib and CD33 CART cells emerged as promising regimens for paediatric and adult patients with KMT2A rearranged AML. Finally, vaccination using host-derived leukaemia cells and donor-derived dendritic cells represents a promising strategy to reduce the relapse risk for AML patients following an allogeneic transplant.

(BELG J HEMATOL 2024;15(1):22–6)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top